Mizuho Securities Reiterates Buy on Allergan (AGN) Following a 4Q Earnings Beat

Allergan's (AGN) Quarter Not Strong Enough to Support Price Target - PiperJaffray

February 23, 2016 8:23 AM EST

Allergan (NYSE: AGN) posted a solid 4Q leading Piper Jaffray analyst, David Amsellem, to reiterate his Overweight rating but trim his price target as estimates roll forward.

AGN reported non-GAAP diluted EPS of $3.41 on revenues of $4.2B, versus the Street estimates of $3.36 and $4.2B. Performance across several key product franchises remained strong, with total brand revenue in 4Q15 growing by 11% over 4Q14 (excluding foreign exchange headwinds and the erosion of the immediate-release form of Namenda due to generics).

The company has strong visibility on continued brisk volume growth for key... More

Allergan's revenue beats on higher U.S. brand sales

February 22, 2016 7:46 AM EST

(Reuters) - Allergan Plc (NYSE: AGN) reported better-than-expected quarterly revenue, helped by strong performance in its U.S. brands segment, and said it continues to expect its takeover by Pfizer Inc (NYSE: PFE) to close in the second half 2016.

The company's shares rose 3.2 percent to $284.

Allergan said revenue in its U.S. brands business rose 38 percent to about $2.5 billion in the quarter ended Dec. 31, accounting for 58.7 percent of total revenue.

... More

Allergan (AGN) Tops Q4 EPS by 5c

February 22, 2016 7:32 AM EST

Allergan (NYSE: AGN) reported Q4 EPS of $3.41, $0.05 better than the analyst estimate of $3.36. Revenue for the quarter came in at $4.2 billion versus the consensus estimate of $4.2 billion.

GUIDANCE:

Allergan sees FY2016 revenue of abot $17 billion, versus the consensus of $17.66... More

Trading Radar for 2/22: Fitbit (FIT), Rogers (ROG), Dean Foods (DF), Motorola Solutions (MSI), On Deck Capital (ONDK) Report

February 19, 2016 2:14 PM EST

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Earnings:

Allergan (NYSE: AGN) - consensus EPS $3.36
Armstrong World (NYSE: AWI) - consensus EPS $0.33
Cobalt International Energy (NYSE: CIE) - consensus loss $0.15
Dean Foods (NYSE: DF) - consensus EPS $0.34
Education Realty Trust (NYSE: EDR) - consensus EPS $0.61
First Potomac Realty Trust (NYSE:... More

Mizuho Maintains Bullish View on Allgergan (AGN) Into EPS

February 19, 2016 8:38 AM EST

Mizuho analyst, Irina Koffler, thinks Allergan (NYSE: AGN) is fully priced as a standalone entity but the stock can have additional upside on the Pfizer integration. Near term, the company could see volatility leading to a longer term opportunity. No change to Buy rating or... More

Wells Fargo Starts Allergen (AGN) at Outperform

February 19, 2016 8:19 AM EST

Wells Fargo initiated coverage on Allergen (NYSE: AGN) with an Outperform rating.

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $277.98 yesterday.

... More

Teva offers EU concessions over Allergan generics deal

February 19, 2016 5:51 AM EST

By Foo Yun Chee

BRUSSELS (Reuters) - Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has offered concessions to allay EU antitrust concerns over its $40.5 billion bid for Allergan's (NYSE: AGN) generics unit which will cement its position as the world's largest generics drugmaker.

"Commitments have been submitted and the... More